Enhanced Pharmaceuticals, Inc. Enhancing the Safety and Efficacy of Pharmaceuticals. SAFE HARBOR STATEMENT.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Enhancing the Safety and Efficacy of Pharmaceuticals
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and in Enhanced Pharmaceuticals’ compounds under development in particular; the potential failure of Enhanced Pharmaceuticals’ compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhanced Pharmaceuticals’ compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhanced Pharmaceuticals’ business, structure or projections; the development of competing products; uncertainties related to Enhanced Pharmaceuticals’ dependence on third parties and partners. Enhanced Pharmaceuticals' disclaims any obligation to update these forward-looking statements.
1. Maintain market share
2. Need solutions for: new drugs, price & generics
3. Life cycle maintenance:
A. SAFER VERSIONS OF EXISTING LARGE MARKET DRUGS – MONITIZE BY CO-VENTURES WITH MAJOR PHARMACEUTICAL COMPANIES
B. GENERATE REFORMULATION PATENTS BASED ON MAMMALIAN CELL AND ANIMAL MODEL DATA. MONITIZE BY OUT-LICENSING OR INTERNAL DEVELOPMENT
PotentialTherapeutic Targets30-50% of all drugs target GPCRs
Note: Recommended use of inhalers is 2x/day. Studies have shown that on arriving at an ER many asthmatics have taken as many as 20 puffs in the preceding hour
Drug tolerance often occurs with repeated or continuous administration of a drug.
A person's response to the drug decreases and they require larger doses to achieve the desiredtherapeutic effects. This produces a loss of efficacy and an increase in serious side effects.
Treatment with Isoproterenol
Desensitized and tested with Isoproterenol alone;
Desensitized and treated with our drug combination